Groowe Groowe BETA

US Stock Market News

Stay on top of the US stock market with real-time breaking news and market-moving stories. Our platform continuously aggregates updates from trusted financial news sources, giving traders and investors a fast overview of events that may impact stock prices.

Whether you're tracking specific companies or scanning the broader market, the news feed helps you quickly identify important developments as they happen.

Create an account to access the live news feed. Access is free while the platform is in beta. Visitors without an account can still browse the latest headlines with a 15-minute delay.

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Tuya Smart Launches TuyaClaw--Still the Same "Claw," but Actually Does Housework

prnewswire.com
TUYA

AIXCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Strategic Real Estate Industry Engagement, Long-Term Infrastructure Direction, and Industry Signals From the Evolving AI Stack

prnewswire.com
AIXC

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

globenewswire.com
REGN SNY

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

globenewswire.com
SNY REGN

Idorsia announces the nomination of three candidates for election to the Board of Directors

globenewswire.com
CHTR

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

globenewswire.com
PHAR PHARM

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

globenewswire.com
REGN SNY

Idorsia announces the nomination of three candidates for election to the Board of Directors

globenewswire.com
AZN

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

globenewswire.com
REGN SNY

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

globenewswire.com
PHAR
View all news →